De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined wit...

Full description

Bibliographic Details
Main Authors: Claudia Piombino, Marco Oltrecolli, Elena Tonni, Marta Pirola, Rossana Matranga, Cinza Baldessari, Stefania Pipitone, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
metastatic hormone-sensitive prostate cancer
new hormonal agents
transcriptomic profiling
DNA damage repair genes
tumor suppressor genes
androgen receptor
Online Access:https://www.mdpi.com/2072-6694/15/20/4945

Internet

https://www.mdpi.com/2072-6694/15/20/4945

Similar Items